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Diagnosing Sporadic Creutzfeldt-Jakob Disease
by the Detection of Abnormal Prion Protein in Patient Urine
Connie Luk, PhD; Samantha Jones, BSc; Claire Thomas, BSc; Nick C. Fox, MD; Tze H. Mok, MBChB;
SimonMead, PhD; John Collinge, FRS; Graham S. Jackson, PhD
IMPORTANCE Creutzfeldt-Jakob disease (CJD) is a fatal neurodegenerative disorder
associated with the accumulation of infectious abnormal prion protein through amechanism
of templatedmisfolding. A recent report has described the detection of abnormal prion
protein in the urine of patients with variant CJD (vCJD) using protein misfolding by cyclic
amplification, which was apparently absent in themore common sporadic form of CJD
(sCJD). A noninvasive diagnostic test could improve early diagnosis of sCJD and, by screening
donations, mitigate the potential risks of prion transmission through human urine–derived
pharmaceuticals. Here, we describe the adaptation of the direct detection assay, developed
originally as a blood test for vCJD, for the detection of disease-associated prion protein in
urine samples from patients with sCJD.
OBJECTIVE To determine the feasibility of sCJD diagnosis by adaptation of an established
vCJD diagnostic blood test to urine.
DESIGN, SETTING, AND PARTICIPANTS This retrospective, cross-sectional study included
anonymized urine samples from healthy nonneurological control individuals (n = 91), patients
with non-prion neurodegenerative diseases (n = 34), and patients with prion disease (n = 37)
of which 20 had sCJD. Urine samples obtained during theMedical Research Council PRION-1
Trial, the National PrionMonitoring Cohort Study, and/or referred to the National Prion Clinic
or Dementia Research Centre at the National Hospital for Neurology and Neurosurgery in the
United Kingdom.
MAIN OUTCOMES ANDMEASURES Presence of sCJD infection determined by an assay that
captures, enriches, and detects disease-associated prion protein isoforms.
RESULTS A total of 162 samples were analyzed, composed of 91 normal control individuals
(51 male, 33 female, and 7 not recorded), 34 neurological disease control individuals (19 male
and 15 female), and 37 with prion disease (22male and 15 female). The assay’s specificity for
prion disease was 100% (95% CI, 97%-100%), with no false-positive reactions from 125
control individuals, including 34 from a range of neurodegenerative diseases. In contrast to
a previous study, which used a different method, sensitivity to vCJD infection was low
(7.7%; 95% CI, 0.2%-36%), with only 1 of 13 patients with positive test results, while
sensitivity to sCJDwas unexpectedly high at 40% (95% CI, 19%-64%).
CONCLUSIONS AND RELEVANCE We determined 40%of sCJD urine sample results as positive.
To our knowledge, this is the first demonstration of an assay that can detect sCJD infection in
urine or any target analyte outside of the central nervous system. Urine detection could allow
the development of rapid, molecular diagnostics for sCJD and has implications for other
neurodegenerative diseases where disease-related assemblies of misfolded proteins might
also be present in urine.
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P rion diseases are lethal, transmissible neurodegenera-tive conditions of humans and animals caused bymis-folding and aggregation of the prion protein (PrP).1,2 It
is the transmissibility of disease that is a defining feature of
the group and has resulted in several high-profile epidemics
of acquired prion disease, including, for example, kuru in hu-
mans, bovine spongiformencephalopathy incattle, and itshu-
man counterpart variant Creutzfeldt-Jakob disease (vCJD).3
Prion disease may also occur as sporadic CJD (sCJD) without
anyobvious exposure to an infectious source, the clinical syn-
drome being rapidly progressive with a median survival of
around 4 months.4 Central to the pathogenesis of prion dis-
ease is the autocatalytic, templated remodeling of the host’s
normal cellular PrP, leading to accumulation of abnormal PrP
isoformstypifiedby insolubleaggregatesoftentermedPrPSc.5-8
It is increasingly recognized thatmore commonneurodegen-
erativediseases, such asAlzheimerdisease, also involve simi-
lar seeding processes and worldwide efforts are now being
made to establish the precise role of prionlikemechanisms in
a range of human diseases.9-12
As a consequence of widespread exposure to bovine
spongiformencephalopathyprions, it is thought that asmany
as 1 in 2000of theUKpopulationmay be prion carriers.13 Sig-
nificant public health concerns are associatedwith the trans-
missibility of prion diseases, and the potential prevalence of
vCJD infection has required widespread precautionary mea-
sures to limit iatrogenic transmission. The risks of iatrogenic
transmission from individuals with sCJD have long been es-
tablished,with the primary sources being contaminated neu-
rosurgical instruments and devices14 and cadaveric donor–
derived materials such as dura mater and pituitary growth
hormone.15 The incidenceof sCJD is around2personspermil-
lion per year, which typically occurs with increasing inci-
dence fromlatemiddle ageonwardsandhasauniformsexand
geographical distribution. The lifetime risk for sCJD is around
1 in 5000 in the United Kingdom. Unfortunately, approxi-
mately half of patients are only diagnosed as having the dis-
ease at a clinically advanced state.16
Thepresence of PrPSc andother abnormal isoformsof PrP
is a specific and potentially sensitive diagnostic indicator for
prion disease and methods for their detection have been de-
veloped that canbeapplied to a rangeof tissues and fluids.17-21
The impetus for the development of diagnostic methods has
been theemergenceofvCJD,which is characterizedbyawide-
spread peripheral pathology22 and the infection of blood23,24
and urine.25 Despite the development of an assay for the di-
agnosis of vCJD using blood21,26 and the reporting of vCJD in-
fectionbeingdetectable inurine,25 theapplicationofsuchtech-
niques to sCJD has been confounded by the restriction of
significant pathology to the central nervous system. Coinci-
dent with the reporting of detection in the urine of patients
with vCJD was the failure to detect any signs of infection in
the samples of patientswith sCJDusing the same technique.25
However, themethodusedhasnever been convincinglydem-
onstrated to detect sCJD andnotably no positive control indi-
viduals were included in this study. While the application of
amyloidseedingassays tocerebrospinal fluid (CSF)haveproved
effective for the diagnosis of sCJD, the invasive nature of this
procedurehas limited their application topatientswith ahigh
index of suspicion of prion disease.27
Anoninvasive premortembiochemical test for sCJDdiag-
nosis could significantly reduce the extended time currently
taken to establish a firm diagnosis, which can compose most
of apatient’s remaining life16 and reduce the threshold for test-
ing in patients with relatively early, nonspecific clinical fea-
tures. Here we report the application to urine testing of an
adapted blood assay, originally developed for vCJD.21 Strik-
ingly, the assay was able to detect sCJD infection in almost
half of the patient samples, the first demonstration of an as-
say capable of diagnosing sCJD from urine or any peripheral
analyte.
Methods
Source of Urine Samples
This studywas approvedby the local research ethics commit-
tees of the University College London Institute of Neurology
and theNationalHospital forNeurologyandNeurosurgery.Pa-
tient andcontrol urine sampleswereobtainedwithwritten in-
formed consent from patients enrolled in the Medical Re-
search Council PRION-1 Trial,28 National Prion Monitoring
Cohort Study, and/or referred to the National Prion Clinic or
Dementia Research Centre at the National Hospital for Neu-
rologyandNeurosurgery.DiagnosesofCJDweremadeaccord-
ing toestablishedcriteria.27,29All sampleswerecollectedusing
standard urinalysis preservatives (boric acid, sodium for-
mate, and sodium borate) and stored frozen at −70°C inmul-
tiple aliquots of 2 mL and thawed before use. Samples were
analyzed blind to the operators andonly decoded after analy-
sis and determination of positive or negative status.
Testing Procedure
Samples were tested using amodification of a method previ-
ously described.21 Briefly, 400 μL of each samplewas diluted
1:1 into 400-μL buffer (200mM Tris; 4% weight/volume bo-
vine serumalbumin; 4%weight/volume3-[(3-Cholamidopro-
pyl)dimethylammonio]-1-propanesulfonate; 2 tablets com-
plete protease inhibitors [Roche]; and 80 units of Benzonase
[grade II, Merck]) containing 23 mg of Capture Matrix (CM)
(sub–45-μm stainless steel particles; Goodfellow) and incu-
bated overnight. The CMwas isolated using a magnetic rack,
supernatant discarded, and washed repeatedly with 1 mL of
Key Points
Question Is abnormal prion protein present in the urine of
patients with sporadic Creutzfeldt-Jakob disease?
Findings In this cross-sectional study, 40% of patients with
sporadic Creutzfeldt-Jakob disease excreted abnormal prion
protein in their urine, an indication absent in healthy and
neurological disease control individuals.
Meaning Sporadic Creutzfeldt-Jakob disease can be diagnosed
using urine-based testing and the screening of urine used for the
production of pharmaceuticals may be possible.
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phosphate-buffered saline (PBS) plus 0.05% volume/volume
Tween-20 (PBST). After the final wash, all liquid was re-
movedand theCMheated at 110°C. Toeach tube, 50μLof bio-
tinylatedprimary antibody (ICSM18;D-GenLtd) prepared at 1
μg/mL in PBSplus 1%volume/volumeTween-20 (PBST*)was
added and incubated at 37°C for 1 hour. Sampleswerewashed
repeatedly with 1-mL PBST, isolating CM each time. Each
samplewas then incubatedwithHighSensitivityNeutrAvidin-
HRP (Pierce) prepared at a 1:100000dilution inPBST* at 37°C
for 45 minutes. Samples were again washed repeatedly with
1-mL PBST, isolating CM each time. To each sample, 60 μL of
SuperSignal enzyme-linked immunosorbent assayFemtoche-
miluminescent substrate (Pierce) was added and CM was
evenlydistributed into3 replicatewells of ablack96-well plate
(Greiner).Eachplate includedasetof6quality-control samples
(5 negative control normal urine samples and 1 positive con-
trol sample). An additional 80 μL of chemiluminescent sub-
strate was added to each well immediately prior to the plate
scan.Thetotal luminescentoutputovera fixed integrationtime
wasmeasuredforeachwellusingaM1000plate reader (Tecan).
Positivity Criteria and Data Analysis
Samples were scored reactive if the mean chemilumines-
cence from3replicatewellsexceededanon-platecutoff thresh-
old of themean plus 5 SDs of 5 negative control normal urine
samples. Thus, samples with a ratio relative to cutoff greater
than 1were scored reactive.All sampleswere tested twicewith
those that were repeat reactive (ie, reactive in both analyses
consideredpositive forpriondisease).Nonreactive andsingle-
reactive samples were considered negative.
ConductivityMeasurements
To control for the possibility of dehydration in patients with
prion disease producing higher urine direct detection assay
(DDA) signals, an approximation to the concentration levels
of urine samples was determined by conductivity measure-
ment. Conductivity is known to correlatewith urine osmolal-
ity and specific gravity30,31 and was determined using a low-
volume conductivity meter (Horiba Laqua Twin B-771).
Calibration of the conductivity meter was performed using a
1.41-mS/cm standard solution and the conductivity of urine
samplesdeterminedby taking themeanof3 independentmea-
surements from3 separate aliquots of 100μLof urine sample,
washing the electrode with double-distilled water between
readings.
Results
DDAAnalysis of Urine FromPatientsWith Prion Disease
A panel of urine samples obtained from a total of 37 patients
withconfirmedpriondiseaseand125control individuals, from
both normal individuals and patients with neurological
diseases other thanpriondisease,were analyzedusing an ad-
aptation of a previously reported DDA blood test for vCJD in-
fection.Thesampleswere tested ingroupsof 12,withaquality-
control panel on each plate consisting of 5 negative normal
control samplesand1positivecontrol sample.Eachsamplewas
tested in triplicate wells across 2 independent runs. An arbi-
trary cutoff was determined from the mean plus 5 SDs of the
panel of 5 normal samples in the quality-control panel. A ra-
tio for themeanchemiluminescenceofeachsample to theplate
cutoff was calculated for each sample and, if greater than 1,
a samplewas classified as reactive.Only samples thatwere re-
peat reactive in both test runs were scored as positive. Of the
162 blinded samples tested, 15 and 22 sampleswere scored as
reactive in the first and second test runs, respectively,with 10
samples scored repeat reactive across the2 test runs (Figure 1).
All of the 10 positive samples were from patients with prion
disease (1 from a case of vCJD, 1 from a growth hormone–
related case of iatrogenic CJD, and8 frompatientswith sCJD).
A summaryof themajor clinical findings inall 37 casesofprion
disease is provided in the eTable in the Supplement.
There were no clear associations with any aspects of the
clinical history, diseaseprogression, or investigations.TheNa-
tional Prion Clinic has developed a functionally oriented rat-
ing scale tomeasureCJDdisease progression termed theMRC
PrionDisease Rating Scale.4 ThemeanMRCScale scorewas 4
of 20 forpositive cases and5 fornegative cases (P = .57; t test).
Thepatientwith least diseaseprogressionof sCJDhadanMRC
Scale score of 10 of 20. However, at present, most sCJD cases
in the United Kingdom are diagnosed at advanced clinical
stages for a variety of reasons; we had no samples from any
patient with sCJD at earlier disease stages. All genotypes at
polymorphic codon 129 of the prion protein gene, an impor-
tant susceptibility factor and disease modifier,32 were repre-
sented in both DDA positive and negative cases. Typical in-
vestigation findings, includingperiodic sharpwavecomplexes
on electroencephalography, abnormal signal on diffusion-
weightedbrainmagnetic resonance imaging in the cortex and
basal ganglia, and abnormal 14-3-3 protein levels in CSFwere
found in an expected proportion of DDA positive and nega-
tive cases (eTable in the Supplement).
Based on the criteria of a sample being repeat reactive in
2 independent runs, 10 of 37 (27%) of the prion disease urine
samples were identified in the absence of any false-positive
reactions. However, considering sCJD in isolation, sensitivity
ofdetectionwas8of20samples (40%;95%CI, 19%-64%),with
100% specificity (95% CI, 97%-100%).
Comparison of the mean DDA results expressed as ratios
relative tocutoffs for the4 typesofpriondiseaseanalyzedcon-
firms significantly elevated abnormal PrP levels in both sCJD
and iatrogenic CJDwith respect to control (P < .001), butwith
levels in both vCJD and inherited prion disease failing to
achievestatistical significance,possiblyowing to the lownum-
bers of samples analyzed (Figure 2).
Conductivity of Urine Samples As aMeasure
of Concentration
Conductivity, a simplified measure of osmolality that corre-
lateswith urine concentration,30,31 wasmeasured in approxi-
mately a third of the samples (n = 55), where sufficient vol-
umewasavailable.Nocorrelationwasobservedbetweenurine
concentration andDDA signals, confirming patient hydration
was not the cause of elevated abnormal PrP signals in urine
(Figure 3).
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Discussion
Blood is a commonlyusedanalyte for a rangeofdiagnostic and
prognostic tests, being readily accessiblewithminimal risk in
almost all patients.Wehavepreviously reported thedevelop-
ment and validation of a blood test for vCJD,21,26 which de-
spite excellent performance characteristics against vCJDwas
unable to detect infection in the blood of patients with sCJD.
Anaccuratediagnosisof sCJD inpatientswithadvancedsymp-
tomatic disease canusually be achieved16without recourse to
moleculardiagnosticsbut theability todiagnosedisease inpa-
tients much earlier would have obvious benefits, particular
with respect to early entry into therapeutic trials.
The ability of disease-associated abnormal PrP to cata-
lyze the conversion of recombinant PrP into amyloid confor-
mations has been exploited in the development of amyloid-
seeding assays capable of detecting the presence of prion
disease infection in a variety of tissues and fluids.18,19,33How-
ever, thedetectionof sCJDprion infectionhas been limited to
the tissuesof thecentralnervous systemandCSF. Inonestudy,
analysis of CSF obtained from patients with sCJD using amy-
loid seeding indicated the detection limit is sufficient for ex-
cellent discriminationof affected individuals fromcontrol in-
dividuals, with a sensitivity of around 90%.34 However, the
requirement for CSF limits the application of the assay, as the
collectionof such samples is an invasiveprocedure that is gen-
erally performed only when significant neurological symp-
toms and signs are evident.
Analternative tobloodasaperipheral analyte, andonethat
canbe readilyobtained for routinediagnosticuse, isurine.Our
study has shown for the first time, to our knowledge, that it is
feasible to identify sCJDusingaurine samplebycaptureofdis-
ease-associated PrP on a stainless steel matrix and detection
Figure 1. Assaying a Blind Panel of 162 Urine Samples
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Testing was performed in 2 independent assays on a blind panel of 162 urine
samples from patients with diagnoses of sporadic Creutzfeldt-Jakob disease
(sCJD; n = 20), variant CJD (vCJD; n = 13), inherited prion disease (IPD; n = 2),
and growth hormone–related iatrogenic CJD (iCJD; n = 2) and healthy normal
and neurological disease control individuals (n = 91 and n = 34, respectively).
Neurological disease control individuals comprised those with Alzheimer
disease (n = 21), Huntington disease (n = 3), frontotemporal dementia (n = 3),
familial Alzheimer disease (n = 2), and early-onset dementia (n = 1) and referrals
to the Nation Prion Clinic determined as non-prion disease (n = 4). Runs 1 and 2
represent data from the individual assay runs of blind samples. Data are shown
as the chemiluminescent signal ratio relative to a cutoff determined from the
mean +5 x SD of normal control individuals (see theMethods section).
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using anti-PrPmonoclonal antibodies.While the sensitivity of
diagnosis is relatively low, at 40%, the highmean signals ob-
tained in the assay suggest this could be improved consider-
ably by pretreatment or processing of large volumes of urine
prior toassay. It is likely thecurrentdiagnostic sensitivitycould
besignificantlyenhancedby improvements in theanalytic sen-
sitivity of the assay but it is unclear whether this could ap-
proach 100%, as there is likely to be variability in the pres-
ence and concentration of abnormal PrP in the urine of
individual patients. The high mean signals observed in the 2
samples fromcasesof growthhormone–related iatrogenicCJD
suggest such an assaymay also have significant sensitivity to
casesof secondaryCJD infection, although thiswill require the
analysis of larger numbers of samples. The detection of ab-
normalmisfoldedPrP in theurineofpatientswithCJD is some-
what unexpected and intriguingly suggests other neurode-
generative diseases associated with protein misfolding may
have diagnostic urine signatures. An unparalleled advantage
of urine as an analyte is the easy availability of large sample
volumes for research,whichwill facilitate thedevelopmentof
protocols for the isolation and characterization of the spe-
cific formof abnormal PrP present, leading to improved diag-
nostic sensitivity.
The origin of disease-associated PrP in the urine of pa-
tients with sCJD is unknown, but it is clear that urine con-
tains cellular PrP, largely in a truncated form that carries only
a partial glycosylphosphatidylinositol anchor lacking the as-
sociated lipid moiety35,36 and, therefore, there is the poten-
tial for prion replication in situ as well as accumulation from
the glomerular filtration of blood. Althoughurine is normally
considered to lack detectable protein in the absence of kid-
neydisease, in fact,normalkidney functionresults in tracepro-
tein concentrations of between 50 and 200 μgmL−1, which is
sufficient to result in the accumulation of abnormal PrP de-
rived from blood. It is notable that although abnormal PrP is
present in urine, it is not readily detectable in blood. A plau-
sible explanation is the enrichment of abnormal PrPby the ac-
tion of filtration in the kidney to concentrations that are de-
tectable, but this could also be explained by active prion
replication in the kidney or urinary tract. Certainly all the re-
quirements for prion amplification are present: normal cellu-
lar PrP, disease-associated abnormal PrP, and a slightly dena-
turingenvironmentprovidedbyurea.However, it is important
to note that transmission studies have indicated the poten-
tial prion titers in native urine are low (<0.38 infectious
units/mL−1)37 or absent, and there areno reported cases ofCJD
resulting fromsexual transmission,with theevidence fromex-
perimentalmodels indicating that this isunlikely tooccur.38,39
The complex milieu of blood contributes to greater difficul-
ties in specifically detecting disease-related signals whereas
urine is a relatively “clean” analyte,with lowbackground lev-
els of protein, which may be sufficient to account for the ap-
parent discrepancy alone.
Prion protein has previously been identified in commer-
cially available injectable urine-derived gonadotropin prod-
ucts that are used to treat infertility in women40 and unde-
scended testes inboys41 andare available for illicit use inbody
building and as performance-enhancing drugs.42 This fact,
coupledwith thedetectionof abnormal PrP in theurine of pa-
tientswithvCJD,25has raisedquestionsabout thesafetyof such
products should the purificationmethods result in the copu-
rification of prions as is known to have been the case for hu-
man cadaveric pituitary-derivedhormones.15 Typically, urine
is sourced frompostmenopausalwomenwith amedian ageof
Figure 3. Correlation of Urine Sample Direct Detection Assay Values
and Conductivity
8
6
4
2
0
0 4030
M
ea
n 
Di
re
ct
 D
et
ec
tio
n 
As
sa
y 
Re
su
lt
s,
Ra
tio
s R
el
at
iv
e 
to
 C
ut
of
fs
Mean Conductivity, mS/cm
2010
The conductivities of 55 urine samples were quantified as milliSiemens per cm
and plotted vs themean of the previously determined ratios relative to cutoff
values on the y-axis. A Pearson correlation coefficient was calculated as 0.058
for the association between the 2 values, which was not significantly different
from 0 (P = .68; 2-tailed t test). The blue line superimposed on the data is the
best fit of a linear regression, highlighting the lack of correlation with a gradient
of 0.002.
Figure 2. Discrimination of Various Forms of Prion Disease FromNormal
and Neurological Control Individuals
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Data shown are the groupmean ratios relative to cutoffs for both assay runs
combined for the groups of samples indicated; 91 normal control individuals
and 34 neurological disease control individuals (for details see Figure 1 legend),
13 with variant Creutzfeldt-Jakob disease (vCJD), 20 with sporadic
Creutzfeldt-Jakob disease (sCJD), 2 with inherited prion disease (IPD), and
2 with iatrogenic inherited prion disease (iCJD). Error bars represent the SEM.
The 2-tailed P values for comparison of control samples with prion disease
cohorts support a significant difference for both sCJD and iCJD.
a P < .001.
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older than 50 years, an age cohort where sCJD can be ex-
pected, althoughexclusion criteria exist for donations, analo-
gous to those in place for donating blood. Despite transmis-
sion studies indicating thepotential prion titers innativeurine
are low,37 it is conceivable that commercial purificationofhor-
moneproducts could concomitantly enrich for prion infectiv-
ity. Our finding, that the urine of patients with sCJD contains
abnormal PrP is consistent with concerns that urine-derived
fertility products could contain infectious prions as sCJD re-
mains themost common form of prion disease and has a uni-
form worldwide incidence.
Our findings are in marked contrast to those recently re-
portedusing the techniqueofproteinmisfoldingby cyclic am-
plification, where a high sensitivity for the detection of vCJD
infection in urine was observed and yet none of the 68 pa-
tient samples from sCJD tested positive.25 A critical limita-
tionto the interpretationof this finding is that theassaymethod
(protein misfolding by cyclic amplification) has never been
convincingly demonstrated to detect sCJD and indeed no
positive controls were included in this study. Parallel CJD
strain–dependent differences are observed with other assay
methods, some ofwhich are attributable to differences in pe-
ripheral pathogenesis21,22,43,44 but some of which remain
unexplained.45
Conclusions
The detection of disease-related PrPs in the urine of patients
with sCJD is the first demonstration that sCJD can be diag-
nosed from urine of any peripheral analyte by biochemical
means. This offers the possibility of improved early diagnosis
of sCJD and the potential precautionary screening of human
urine–derived pharmaceuticals.
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